Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 7/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 7/20 | 0.38 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17636177 | 0.83 | NOTUM (0.63) | NOTUMXIAPBIRC2AMPD2 | |
| SCHEMBL430124 | 0.83 | NOTUM (0.64) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL9687259 | 0.83 | NOTUM (0.64) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL395606 | 0.81 | NOTUM (0.62) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL31481108 | 0.81 | NOTUM (0.62) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL17446878 | 0.81 | NOTUM (0.62) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL31481087 | 0.81 | NOTUM (0.62) | NOTUMCNR2XIAPBIRC2AMPD2 | |
| SCHEMBL1612802 | 0.80 | NOTUM (0.39) | NOTUMCNR2XIAPBIRC2 | |
| SCHEMBL17447342 | 0.80 | NOTUM (0.60) | NOTUM | |
| SCHEMBL15032891 | 0.79 | NOTUM (0.59) | NOTUMCNR2XIAPBIRC2AMPD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2049115-B1 | ALKYNE-SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2049115-B1 | ALKYNE-SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8063055-B2 | Substituted pyridone compounds and methods of use | AMGEN INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2008008493-A2 | ALKYNE-SUBSTITUTED PYRIDONE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-7148221-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7144888-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1717220-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1688408-A2 | Vanilloid receptor ligands and their use in treatments | Amgen, Inc (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272777-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NOTUM 4177/4885CNR2 171/4885XIAP 2184/4885 |
| US-20050277631-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NOTUM 4177/4885CNR2 171/4885XIAP 2184/4885 |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | NOTUM 4008/4885CNR2 1496/4885XIAP 202/4885 |
| US-20040082780-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | NOTUM 3991/4885CNR2 150/4885XIAP 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.